All Stories

  1. Depressive and Biopsychosocial Frailty Phenotypes: Impact on Late-life Cognitive Disorders

    Article • Journal of Alzheimer s Disease, August 2023, IOS Press

    Madia Lozupone

  2. Age-Related Central Auditory Processing Disorder, MCI, and Dementia in an Older Population of Southern Italy

    Article • Otolaryngology, April 2020, SAGE Publications

    Madia Lozupone

  3. Traditional Dietary Patterns and Risk of Mortality in a Longitudinal Cohort of the Salus in Apulia Study

    Article • Nutrients, April 2020, MDPI AG

    Francesco Panza, Madia Lozupone

  4. The association of patient-reported symptoms and clinical and lung function parameters in patients with chronic obstructive pulmonary disease in stable phase

    Article • Expert Review of Respiratory Medicine, April 2020, Taylor & Francis

    Francesco Panza, Madia Lozupone

  5. Social determinants of late-life depression epigenetics

    Article • Epigenomics, April 2020, Future Medicine

    Madia Lozupone

  6. Development of disease-modifying drugs for frontotemporal dementia spectrum disorders

    Article • Nature Reviews Neurology, March 2020, Springer Science + Business Media

    Dr Bruno P Imbimbo, Francesco Panza, Madia Lozupone

  7. Relationship between Inflammatory Food Consumption and Age-Related Hearing Loss in a Prospective Observational Cohort: Results from the Salus in Apulia Study

    Article • Nutrients, February 2020, MDPI AG

    MD Marco Castellana, Madia Lozupone, Francesco Panza

  8. Corrigendum to “Nutritional interventions and cognitive-related outcomes in patients with late-life cognitive disorders: A systematic review” Neurosci. Biobehav. Rev. 95 (2018) 480–498

    Article • Neuroscience & Biobehavioral Reviews, January 2020, Elsevier

    Madia Lozupone, Dr Vittorio Dibello

  9. The Challenge of Antidepressant Therapeutics in Alzheimer’s Disease

    Article • January 2020, Springer Science + Business Media

    Madia Lozupone

  10. Do anti-amyloid-β drugs affect neuropsychiatric status in Alzheimer’s disease patients?

    Article • Ageing Research Reviews, November 2019, Elsevier

    Madia Lozupone, Dr Bruno P Imbimbo

  11. Pharmacogenetics in the clinical analysis laboratory: clinical practice, research, and drug development pipeline

    Article • Expert Opinion on Drug Metabolism & Toxicology, September 2019, Taylor & Francis

    Madia Lozupone

  12. Time to test antibacterial therapy in Alzheimer’s disease

    Article • Brain, August 2019, Oxford University Press (OUP)

    Madia Lozupone, Dr Bruno P Imbimbo, Francesco Panza

  13. Episodic memory and learning rates in amyotrophic lateral sclerosis without dementia

    Article • Cortex, August 2019, Elsevier

    Madia Lozupone

  14. Biopsychosocial frailty and the risk of incident dementia: The Italian longitudinal study on aging

    Article • Alzheimer s & Dementia, August 2019, Elsevier

    Madia Lozupone

  15. The Age-Related Central Auditory Processing Disorder: Silent Impairment of the Cognitive Ear

    Article • Frontiers in Neuroscience, June 2019, Frontiers

    Madia Lozupone

  16. Do BACE inhibitor failures in Alzheimer patients challenge the amyloid hypothesis of the disease?

    Article • Expert Review of Neurotherapeutics, May 2019, Taylor & Francis

    Madia Lozupone, Dr Bruno P Imbimbo, Francesco Panza

  17. Disease-modifying therapies for tauopathies: agents in the pipeline

    Article • Expert Review of Neurotherapeutics, April 2019, Taylor & Francis

    Professor Francesco Panza, Madia Lozupone, Professor GIANCARLO G LOGROSCINO, Dr Bruno P Imbimbo, Francesco Panza

  18. Promising therapies for the treatment of frontotemporal dementia clinical phenotypes: from symptomatic to disease-modifying drugs

    Article • Expert Opinion on Pharmacotherapy, April 2019, Taylor & Francis

    Professor GIANCARLO G LOGROSCINO, Madia Lozupone, Vittorio Dibello, Dr Bruno P Imbimbo, Dr Vittorio Dibello

  19. Hydroxytryptamine transporter gene-linked polymorphic region (5HTTLPR) is associated with delusions in Alzheimer’s disease

    Article • Translational Neurodegeneration, February 2019, Springer Science + Business Media

    Madia Lozupone, Francesco Panza

  20. Understanding frailty to predict and prevent dementia

    Article • The Lancet Neurology, February 2019, Elsevier

    Madia Lozupone

  21. Amyloid-β immunotherapy for alzheimer disease: Is it now a long shot?

    Article • Annals of Neurology, January 2019, Wiley

    Madia Lozupone, Dr Bruno P Imbimbo, Francesco Panza

  22. Botulinum Toxin Type A for the Treatment of Lower Limb Spasticity after Stroke

    Article • Drugs, January 2019, Springer Science + Business Media

    Madia Lozupone

  23. A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease

    Article • Nature Reviews Neurology, January 2019, Springer Science + Business Media

    Madia Lozupone, Dr Bruno P Imbimbo, Francesco Panza

  24. Are antibodies directed against amyloid-β (Aβ) oligomers the last call for the Aβ hypothesis of Alzheimer's disease?

    Article • Immunotherapy, January 2019, Future Medicine

    Madia Lozupone, Dr Bruno P Imbimbo, Dr Vittorio Dibello

  25. The Role of Biomarkers in Psychiatry

    Article • January 2019, Springer Science + Business Media

    Madia Lozupone

  26. Nutritional interventions and cognitive-related outcomes in patients with late-life cognitive disorders: A systematic review

    Article • Neuroscience & Biobehavioral Reviews, December 2018, Elsevier

    Madia Lozupone, Dr Vittorio Dibello

  27. Sensorial frailty: age-related hearing loss and the risk of cognitive impairment and dementia in later life

    Article • Therapeutic Advances in Chronic Disease, November 2018, SAGE Publications

    Professor Francesco Panza, Madia Lozupone, Francesco Panza, Dr Vittorio Dibello

  28. BACE inhibitors in clinical development for the treatment of Alzheimer’s disease

    Article • Expert Review of Neurotherapeutics, October 2018, Taylor & Francis

    Madia Lozupone, Vittorio Dibello, Professor GIANCARLO G LOGROSCINO, Dr Vittorio Dibello, Dr Bruno P Imbimbo, Francesco Panza

  29. Social Dysfunction in Older Age and Relationships with Cognition, Depression, and Apathy: The GreatAGE Study

    Article • Journal of Alzheimer s Disease, September 2018, IOS Press

    Francesco Panza, Madia Lozupone, Dr Bruno P Imbimbo

  30. CYP2D6 genotypes in revolving door patients with bipolar disorders

    Article • Medicine, September 2018, Wolters Kluwer Health

    Madia Lozupone

  31. Nutritional Intervention as a Preventive Approach for Cognitive-Related Outcomes in Cognitively Healthy Older Adults: A Systematic Review

    Article • Journal of Alzheimer s Disease, June 2018, IOS Press

    Francesco Panza, Madia Lozupone, Dr Vittorio Dibello

  32. Pharmacotherapy for the treatment of depression in patients with alzheimer’s disease: a treatment-resistant depressive disorder

    Article • Expert Opinion on Pharmacotherapy, May 2018, Taylor & Francis

    Prof Nicola Quaranta, Madia Lozupone, Vittorio Dibello, Dr Vittorio Dibello

  33. Different Cognitive Frailty Models and Health- and Cognitive-related Outcomes in Older Age: From Epidemiology to Prevention

    Article • Journal of Alzheimer s Disease, March 2018, IOS Press

    Madia Lozupone, Dr Vittorio Dibello

  34. Executive Dysfunction Detected with the Frontal Assessment Battery in Alzheimer’s Disease Versus Vascular Dementia

    Article • Journal of Alzheimer s Disease, February 2018, IOS Press

    Francesco Panza, Madia Lozupone

  35. Additive Role of a Potentially Reversible Cognitive Frailty Model and Inflammatory State on the Risk of Disability: The Italian Longitudinal Study on Aging

    Article • American Journal of Geriatric Psychiatry, November 2017, Elsevier

    Madia Lozupone, Francesco Panza

  36. The potential of solanezumab and gantenerumab to prevent Alzheimer’s disease in people with inherited mutations that cause its early onset

    Article • Expert Opinion on Biological Therapy, October 2017, Taylor & Francis

    Madia Lozupone, Dr Bruno P Imbimbo, Francesco Panza, Dr Vittorio Dibello

  37. Psychotropic drugs and CYP2D6 in late-life psychiatric and neurological disorders. What do we know?

    Article • Expert Opinion on Drug Safety, October 2017, Taylor & Francis

    Madia Lozupone, Francesco Panza

  38. Cognitive frailty: a potential target for secondary prevention of dementia

    Article • Expert Opinion on Drug Metabolism & Toxicology, September 2017, Taylor & Francis

    Madia Lozupone, Francesco Panza

  39. Innovative biomarkers in psychiatric disorders: a major clinical challenge in psychiatry

    Article • Expert Review of Proteomics, September 2017, Taylor & Francis

    Madia Lozupone, Francesco Panza

  40. Relationships of Dietary Patterns, Foods, and Micro- and Macronutrients with Alzheimer’s Disease and Late-Life Cognitive Disorders: A Systematic Review

    Article • Journal of Alzheimer s Disease, July 2017, IOS Press

    Francesco Panza, Madia Lozupone, Dr Bruno P Imbimbo

  41. Midlife Metabolic Profile and the Risk of Late-Life Cognitive Decline

    Article • Journal of Alzheimer s Disease, July 2017, IOS Press

    Professor GIANCARLO G LOGROSCINO, Francesco Panza, Madia Lozupone, Dr Bruno P Imbimbo

  42. An Old Challenge with New Promises: A Systematic Review on Comprehensive Geriatric Assessment in Long-term Care Facilities

    Article • Rejuvenation Research, June 2017, Mary Ann Liebert Inc

    Francesco Panza, Madia Lozupone, Dr Vittorio Dibello

  43. Role of CLU, PICALM, and TNK1 Genotypes in Aging With and Without Alzheimer’s Disease

    Article • Molecular Neurobiology, June 2017, Springer Science + Business Media

    Francesco Panza, Madia Lozupone

  44. Emerging biomarkers and screening for cognitive frailty

    Article • Aging Clinical and Experimental Research, March 2017, Springer Science + Business Media

    Francesco Panza, Madia Lozupone

  45. Genetics of tailored medicine: Focus on CNS drugs

    Article • Microchemical Journal, February 2017, Elsevier

    Francesco Panza, Madia Lozupone

  46. Reversible Cognitive Frailty, Dementia, and All-Cause Mortality. The Italian Longitudinal Study on Aging

    Article • Journal of the American Medical Directors Association, January 2017, Elsevier

    Francesco Panza, Madia Lozupone, Dr Bruno P Imbimbo

  47. Bipolar Disorder and Frontotemporal Dementia: An Intriguing Association

    Article • Journal of Alzheimer s Disease, December 2016, IOS Press

    Francesco Panza, Madia Lozupone, Dr Bruno P Imbimbo

  48. Pharmacogenetics of neurological and psychiatric diseases at older age: has the time come?

    Article • Expert Opinion on Drug Metabolism & Toxicology, October 2016, Taylor & Francis

    Madia Lozupone, Francesco Panza

  49. Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer’s disease patients

    Article • Expert Opinion on Emerging Drugs, October 2016, Taylor & Francis

    Madia Lozupone, Dr Bruno P Imbimbo, Francesco Panza

  50. The pharmacogenetic road to avoid adverse drug reactions and therapeutic failures in revolving door patients with psychiatric illnesses: focus on the CYP2D6 isoenzymes

    Article • Expert Review of Precision Medicine and Drug Development, September 2016, Taylor & Francis

    Madia Lozupone

  51. Tau-based therapeutics for Alzheimer’s disease: active and passive immunotherapy

    Article • Immunotherapy, September 2016, Future Medicine

    Professor Francesco Panza, Francesco Panza, Madia Lozupone, Dr Bruno P Imbimbo

  52. Psychiatry meets pharmacogenetics for the treatment of revolving door patients with psychiatric disorders

    Article • Expert Review of Neurotherapeutics, July 2016, Taylor & Francis

    Francesco Panza, Madia Lozupone

  53. High doses of incobotulinumtoxinA for the treatment of post-stroke spasticity: are they safe and effective?

    Article • Expert Opinion on Drug Metabolism & Toxicology, June 2016, Taylor & Francis

    Francesco Panza, Madia Lozupone

  54. Tau-directed approaches for the treatment of Alzheimer’s disease: focus on leuco-methylthioninium

    Article • Expert Review of Neurotherapeutics, February 2016, Informa Healthcare

    Francesco Panza, Madia Lozupone, Dr Bruno P Imbimbo

  55. Tau aggregation inhibitors: the future of Alzheimer’s pharmacotherapy?

    Article • Expert Opinion on Pharmacotherapy, February 2016, Informa Healthcare

    Francesco Panza, Madia Lozupone, Dr Bruno P Imbimbo

  56. Klotho Gene and Selective Serotonin Reuptake Inhibitors: Response to Treatment in Late-Life Major Depressive Disorder

    Article • Molecular Neurobiology, February 2016, Springer Science + Business Media

    Madia Lozupone, Francesco Panza

  57. Examination of level of knowledge in Italian general practitioners attending an education session on diagnosis and management of the early stage of Alzheimer's disease: pass or fail?

    Article • International Psychogeriatrics, January 2016, Cambridge University Press

    Madia Lozupone, Dr Bruno P Imbimbo, Francesco Panza

  58. Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer’s Disease

    Article • BioMed Research International, January 2016, Hindawi Publishing Corporation

    Francesco Panza, Madia Lozupone, Dr Bruno P Imbimbo

  59. Alternative pharmacological treatment options for agitation in Alzheimer’s disease

    Article • Geriatric Care, November 2015, PAGEPress Publications

    Francesco Panza, Madia Lozupone

  60. Progresses in treating agitation: a major clinical challenge in Alzheimer’s disease

    Article • Expert Opinion on Pharmacotherapy, September 2015, Informa Healthcare

    Francesco Panza, Madia Lozupone, Dr Bruno P Imbimbo

  61. Psychopathological profile and health-related quality of life (HRQOL) in patients with hepatocellular carcinoma (HCC) and cirrhosis

    Article • Clinical and Experimental Medicine, December 2013, Springer Science + Business Media

    Madia Lozupone

  62. Metabolic Syndrome: Differences between Psychiatric and Internal Medicine Patients

    Article • The International Journal of Psychiatry in Medicine, April 2013, SAGE Publications

    Madia Lozupone

  63. Genetically Determined Measures of Striatal D2 Signaling Predict Prefrontal Activity during Working Memory Performance

    Article • PLoS ONE, February 2010, PLOS

    Madia Lozupone